NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Aclarion, Inc. (ACON) Stock Analysis

Aclarion, Inc. (ACON) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

ACON

$2.35

+$0.06 (+2.62%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACON with… →

ACON Key Statistics

As of Sep 4, 2026
Trading
Open
$2.26
Previous Close
$2.29
Day's Range
2.26–2.41
52-Week Range
1.95–12.03
Volume
44.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.24
Valuation
Market Cap
$6.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
80.86
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.14
Financials (FY)
Revenue (FY)
$75.73K+65.62%
Net Income (FY)
−$7.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.88M
1-Year Return
−67.81%
Dividend and dates
Avg Volume
61.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACON Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−48.91%
2025−99.65%
2024−95.50%
2023−65.52%
2022 (partial year)−78.68%

As of September 4, 2026.

ACON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$75.73K−$7.23M−9551.9%
2024$45.72K−$6.99M−15293.8%
2023$75.40K−$4.91M−6513.4%
2022$60.44K−$7.07M−11694.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$75.73K$6.83K−$7.05M−$7.23M−9551.9%
2024$45.72K−$38.93K−$5.51M−$6.99M−15293.8%
2023$75.40K−$324.00−$4.88M−$4.91M−6513.4%
2022$60.44K−$4.85K−$5.56M−$7.07M−11694.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACON Valuation vs Health Information Services Median

Median of 53 stocks
MetricACONHealth Information Services medianvs median
P/S ratio80.862.6630.4x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aclarion, Inc. (ACON) at $6.77M. It is classified in the Health Information Services industry, within the Healthcare sector. The company reports 10 employees.

The most recent close on file for ACON is $2.35, dated September 4, 2026. That is +$0.06 (+2.62%) against the previous close. Over the past 52 weeks the price has ranged from $1.95 to $12.03. The latest close sits 20.51% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $75.73K. That is +65.62% against the prior fiscal year, when revenue was $45.72K. The same year closed with a net loss of $7.23M. Profit margin runs at 0%. Trailing earnings per share are −7.14.

Across the 4 fiscal years on file, revenue moves from $60.44K in 2022 to $75.73K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 80.86 times revenue. On price-to-sales that is 30.4 times the Health Information Services median of 2.66. 53 Health Information Services companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.24. Daily returns over the trailing 4 years annualize to a volatility of 170.43%. Over the trailing twelve months the price has returned −67.81%. Measured over 3 years, that is −96.77% a year compounded.

Growth & Income

The record shows no dividend for ACON.

So far in 2026 the price is −48.91%. Across the complete calendar years on file, 2023 returned −65.52% and 2025 returned −99.65%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

Aclarion, Inc. (ACON) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aclarion, Inc. ACON $6.77M —
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
Tempus AI, Inc. TEM $11.66B —

The Health Information Services industry average P/E ratio is 41.1x. Aclarion, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 TEM

Tempus AI, Inc.

$11.66B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aclarion, Inc.

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Visit website →